Hepion Pharmaceuticals Alpha and Beta Analysis

HEPADelisted Stock  USD 0.11  0.01  8.33%   
This module allows you to check different measures of market premium (i.e., alpha and beta) for all equities such as Hepion Pharmaceuticals. It also helps investors analyze the systematic and unsystematic risks associated with investing in Hepion Pharmaceuticals over a specified time horizon. Remember, high Hepion Pharmaceuticals' alpha is almost always a sign of good performance; however, a high beta will depend on investors' risk tolerance level and may signal increased volatility and potential future overvaluation. Key technical indicators related to Hepion Pharmaceuticals' market risk premium analysis include:
Beta
0.58
Alpha
(5.65)
Risk
0.0
Sharpe Ratio
0.0
Expected Return
0.0
Please note that although Hepion Pharmaceuticals alpha is a measure of relative return and represented here as a single number, it indicates the percentage above or below your selected benchmark (i.e., Dow Jones Industrial index.) So in this particular case, Hepion Pharmaceuticals did 5.65  worse than the index. Remember, a high alpha is always good. Beta, on the other hand, measures the volatility (or risk) of an investment. It is an indication of Hepion Pharmaceuticals stock's relative risk over its benchmark. Hepion Pharmaceuticals has a beta of 0.58  . As returns on the market increase, Hepion Pharmaceuticals' returns are expected to increase less than the market. However, during the bear market, the loss of holding Hepion Pharmaceuticals is expected to be smaller as well. .
Alpha is a measure of relative performance on a risk-adjusted basis, while beta measures volatility against the benchmark. The goal is to know if an investor is being compensated for the volatility risk taken. The return on investment might be better than its reference but still not compensate for the assumption of the risk.
  
Check out Risk vs Return Analysis to better understand how to build diversified portfolios. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in inflation.

Hepion Pharmaceuticals Market Premiums

Investors always prefer to have the highest possible return on investment, coupled with the lowest possible volatility. Hepion Pharmaceuticals market risk premium is the additional return an investor will receive from holding Hepion Pharmaceuticals long position in a well-diversified portfolio. The market premium is part of the Capital Asset Pricing Model (CAPM), which most analysts and investors use to calculate the acceptable rate of return on investment in Hepion Pharmaceuticals. At the center of the CAPM is the concept of risk and reward, which is usually communicated by investors using alpha and beta measures. Alpha and beta are two of the key measurements used to evaluate Hepion Pharmaceuticals' performance over market.
α-5.65   β0.58

Hepion Pharmaceuticals Fundamentals Vs Peers

Comparing Hepion Pharmaceuticals' fundamentals to the average values of its peers is one of the most widely used and accepted methods of equity analyses. It helps to analyze Hepion Pharmaceuticals' direct or indirect competition across all of the common fundamentals between Hepion Pharmaceuticals and the related equities. This way, we can detect undervalued stocks with similar characteristics as Hepion Pharmaceuticals or determine the stocks which would be an excellent addition to an existing portfolio. Peer analysis of Hepion Pharmaceuticals' fundamental indicators could also be used in its relative valuation, which is a method of valuing Hepion Pharmaceuticals by comparing valuation metrics with those of similar companies.
    
 Better Than Average     
    
 Worse Than Average Compare Hepion Pharmaceuticals to competition
FundamentalsHepion PharmaceuticalsPeer Average
Return On Equity-4.87-0.31
Return On Asset-1.23-0.14
Current Valuation5.39 M16.62 B
Shares Outstanding10.93 M571.82 M
Shares Owned By Insiders0.19 %10.09 %
Shares Owned By Institutions8.99 %39.21 %
Number Of Shares Shorted448.18 K4.71 M

Hepion Pharmaceuticals Opportunities

Hepion Pharmaceuticals Return and Market Media

The Stock received substential amount of media coverage during this period.
 Price Growth (%)  
       Timeline  
1
12 Health Care Stocks Moving In Thursdays Intraday Session - Benzinga
03/13/2025
2
Hepion Pharmaceuticals enacts reverse stock split - Investing.com
03/19/2025
3
Hepion Pharmaceuticals announces 1-for-50 reverse stock split - MSN
03/27/2025
4
Rensa Filtrations Advanced HEPA Filters Certified to Meet the UL 900 Safety Standards
04/02/2025
5
Hepion Pharmaceuticals Ends Merger with Pharma Two B
04/09/2025
6
Taiwan Air Treatment Systems Market Report - HEPA, Smart Tech and Social Commerce Drive Taiwans Air Treatment Market - ResearchAndMarkets.com
04/14/2025
7
Hepion Pharmaceuticals Executes Binding Letter of Intent with New Day Diagnostics to ...
05/07/2025
8
Hepion Pharmaceuticals Announces Receipt of Delisting Notification from Nasdaq
05/12/2025
9
Hepion Pharmaceuticals Delays Form 10-Q Filing - TipRanks
05/15/2025

About Hepion Pharmaceuticals Beta and Alpha

For many years both, Alpha and Beta indicators are used by professional money managers as critical performance measurement tools across virtually all financial instruments including Hepion or other delisted stocks. Alpha measures the amount that position in Hepion Pharmaceuticals has returned in comparison to a selected market index or another relevant benchmark. In other words, Alpha is the excess return on an investment relative to the performance of your selected benchmark. Beta, on the other hand, measures the relative risk of your investment.

Hepion Pharmaceuticals Upcoming Company Events

As portrayed in its financial statements, the presentation of Hepion Pharmaceuticals' financial position is often influenced by management's estimates, judgments, and sometimes even manipulations. In the best case, Hepion Pharmaceuticals' leadership is honest, while the outside auditors are strict and uncompromising. Whatever the case, investors should always follow all of Hepion Pharmaceuticals' public filing events to personally review all filings and be reasonable and skeptical to interpret all of the financial statements of Hepion Pharmaceuticals. Please utilize our Beneish M Score to check the likelihood of Hepion Pharmaceuticals' management manipulating its earnings.
19th of February 2024
Upcoming Quarterly Report
View
10th of May 2024
Next Financial Report
View
31st of December 2023
Next Fiscal Quarter End
View
19th of February 2024
Next Fiscal Year End
View
30th of September 2023
Last Quarter Report
View
31st of December 2022
Last Financial Announcement
View

Build Portfolio with Hepion Pharmaceuticals

Your optimized portfolios are the building block of your wealth. We provide an intuitive interface to determine which securities in a portfolio should be removed or rebalanced to achieve better diversification, find the right mix of securities that minimizes portfolio risk for a given return, or maximize portfolio expected return for a given risk level.

Build Diversified Portfolios

Align your risk with return expectations

By capturing your risk tolerance and investment horizon Macroaxis technology of instant portfolio optimization will compute exactly how much risk is acceptable for your desired return expectations
Check out Risk vs Return Analysis to better understand how to build diversified portfolios. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in inflation.
You can also try the Content Syndication module to quickly integrate customizable finance content to your own investment portal.

Other Consideration for investing in Hepion Stock

If you are still planning to invest in Hepion Pharmaceuticals check if it may still be traded through OTC markets such as Pink Sheets or OTC Bulletin Board. You may also purchase it directly from the company, but this is not always possible and may require contacting the company directly. Please note that delisted stocks are often considered to be more risky investments, as they are no longer subject to the same regulatory and reporting requirements as listed stocks. Therefore, it is essential to carefully research the Hepion Pharmaceuticals' history and understand the potential risks before investing.
Portfolio Rebalancing
Analyze risk-adjusted returns against different time horizons to find asset-allocation targets
Odds Of Bankruptcy
Get analysis of equity chance of financial distress in the next 2 years
Cryptocurrency Center
Build and monitor diversified portfolio of extremely risky digital assets and cryptocurrency
Economic Indicators
Top statistical indicators that provide insights into how an economy is performing
Premium Stories
Follow Macroaxis premium stories from verified contributors across different equity types, categories and coverage scope
Portfolio Comparator
Compare the composition, asset allocations and performance of any two portfolios in your account
Latest Portfolios
Quick portfolio dashboard that showcases your latest portfolios
Pair Correlation
Compare performance and examine fundamental relationship between any two equity instruments